New draft guidance on biosimilar product labeling issued by US FDA

1 April 2016
biosimilars_samples_large

The US Food and Drug Administration has issued draft new guidance it will give to industry on the labeling of biosimilar products.

This has been published to give the chance for all interested parties – companies, health care providers and patients - to have their say on what is a highly important issue, as labeling communicates a product’s safety and effectiveness to the practitioners who decide whether it is appropriate for patients.

The new guidelines are aimed at ensuring that “new, safe and effective health care options become available for patients”, according to Leah Christl, associate director for therapeutic biologics in the Office of New Drugs in the FDA's Center for Drug Evaluation and Research.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars